VX15/2503 ( DrugBank: - )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
8	Huntington disease	1
13	Multiple sclerosis/Neuromyelitis optica	1

8. Huntington disease

---

Clinical trials : 242 /  Drugs : 205 - (DrugBank : 62) / Drug target genes : 85 - Drug target pathways : 159

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02481674 (ClinicalTrials.gov)	July 2015	19/6/2015	A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of Pepi	A Phase 2, Multi-center, Randomized, Double-blind, Placebo Controlled Study in Subjects With Late Prodromal and Early Manifest Huntington's Disease to Assess the Safety, Tolerability, pk, and Efficacy of Pepinemab	Huntington's Disease	Drug: VX15/2503;Drug: Placebo	Vaccinex Inc.	Huntington Study Group	Completed	21 Years	N/A	All	301	Phase 2	United States;Canada

13. Multiple sclerosis/Neuromyelitis optica

---

Clinical trials : 3,340 /  Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01764737 (ClinicalTrials.gov)	December 2012	3/1/2013	Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS	A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study Of The Safety, Tolerability, And Pharmacokinetics Of Intravenous VX15/2503 In Patients With Multiple Sclerosis	Multiple Sclerosis	Drug: VX15/2503;Drug: Placebo	Vaccinex Inc.	PRA Health Sciences	Completed	18 Years	60 Years	Both	50	Phase 1	United States